All AbMole products are for research use only, cannot be used for human consumption.
ICG-001 selectively inhibits β-catenin/CBP interaction. ICG-001 exhibits growth inhibitory effects in colon carcinoma cell lines (SW480 and HCT-116 cells). ICG-001 also displays efficacy in Min mouse and nude mouse SW620 xenograft models. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer. ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium. Administration of ICG-001 concurrent with bleomycin prevents fibrosis, and late administration is able to reverse established fibrosis and significantly improve survival.
Evid Based Complement Alternat Med. 2022 Jun 28;2022:9705948.
ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway
ICG-001 purchased from AbMole
bioRxiv. 2021 Jun 19;449094.
Immune-evasion of KRAS-mutant lung adenocarcinoma mediated by cAMP response element-binding protein
ICG-001 purchased from AbMole
J Biomed Sci. 2020 Jan 13;27(1):5.
Involvement of collagen XVII in pluripotency gene expression and metabolic reprogramming of lung cancer stem cells.
ICG-001 purchased from AbMole
Onco Targets Ther. 2019 Aug 30;12:7067-7077.
Upregulation of SHIP2 participates in the development of breast cancer via promoting Wnt/β-catenin signaling.
ICG-001 purchased from AbMole
Oncogene. 2015 Sep 17.
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
ICG-001 purchased from AbMole
.jpg) |
Source | Oncogene (2014). Figure 1. ICG-001 was purchased from AbMole BioSciences (Kowloon, Hong Kong, China) |
| Method | microscopy images | |
| Cell Lines | IEC-6 caMEK | |
| Concentrations | 7.5 µ M | |
| Incubation Time | 36 h | |
| Results | "The caMEK-transformed cells showed a partial reversion to an epithelial morphology after treatment of caMEK-transformed cells with ICG-001, a small-molecule antagonist of β-catenin/ TCF-mediated transcription." |
| Cell Experiment | |
|---|---|
| Cell lines | NCI-H929, U266, MM1S, and RPMI-8226 |
| Preparation method | Cells were treated with various concentrations of ICG-001 for 24 hours. 3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) dye was added for the last 4 hours of incubation. Insoluble formazan complexes were pelleted and solubilized with DMSO, and absorbance was measured at 540 nm using a Benchmark Plus microplate spectrophotometer. The IC50 values were calculated using CalcuSyn software. Each experimental condition was done in triplicate and repeated at least once. |
| Concentrations | 0-50 µ M |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | MM tumors were established in SCID-beige mice by subcutaneous inoculation of 1x107 MM RPMI-8226 cells in the right flank |
| Formulation | Solubilized in DMSO and diluted with PBS containing 10% dimethylacetamide and 6% Solutol. |
| Dosages | 100 mg/kg ICG-001 twice a day |
| Administration | administered intraperitoneally |
| Molecular Weight | 548.63 |
| Formula | C33H32N4O4 |
| CAS Number | 780757-88-2 |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Wnt/beta-catenin Products |
|---|
| (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide
(9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp). (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. |
| F7H
F7H is a Frizzled receptor FZD7 antagonist with IC50 of 1.25 μM. F7H is a potent ligand for the FZD7 transmembrane domain (TMD). |
| UU-T02
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction, with a Ki of 1.36 μM. UU-T02 inhibits canonical Wnt signaling. |
| Wnt/β-catenin agonist 1
Wnt/β-catenin agonist 1 is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM. |
| Calphostin C
Calphostin C (PKF115-584) is a small molecule inhibitor of Wnt/beta-catenin/lef-1 signaling. Calphostin C is also a potent and specific inhibitor of protein kinase C. PKF115-584 efficiently killed CLL cells (LC(50)<1 microM), whereas normal B cells were not significantly affected. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
